Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.
The theoretical benefit of a centrifugal pump or heparin coating demonstrated through in vitro or in vivo studies is not recognizable in cardiopulmonary bypass (CPB) during chemical open heart surgery. The objective of this study was to investigate the influence of the interface of air and blood in current CPB with an open circuit system and its relative significance in relationship to the heparin dose and heparin coating. Using the same oxygenator and circuit, an open circuit and closed circuit CPB with the same priming volume were prepared for a 4 h perfusion experiment using diluted and heparinized (3.6 U/ml) fresh human blood. In these experiments, both heparin-coated and noncoated circuits were examined. Blood was sampled before and 2, 30, 60, 120, and 240 min after the start of perfusion, and the platelet and white blood cell counts and beta-thromboglobulin (beta-TG) and C3a levels were measured. The amount of adsorbed protein in the hollow fibers was also measured after retrieval. Although the results demonstrated significantly better biocompatibility of the heparin-coated circuit than the noncoated circuit, the difference between the open and closed circuits was unexpectedly small and insignificant with either the heparin-coated circuit or noncoated circuit. In contrast, the C3a level was higher in the closed circuit than the open circuit. However, the amount of adsorbed protein was markedly lower in the closed circuit (0.7 microgram/cm2) than in the open circuit (11.1 micrograms/cm2). An immunoblot of the adsorbed protein showed a higher density of fibrinogen bands and conversion to fibrin in the open circuit. We speculate that the lower blood C3a level in the open circuit suggests that C3a was taken in by the adsorbed protein. In conclusion, analysis of the adsorbed protein indicates the lower biocompatibility of the open circuit. Similar experiments with less heparin use and more severe conditions will be necessary to elucidate the essential benefit of making a CPB closed circuit.
Nishida
H
H
Department of Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women's Medical University, Japan.
Aomi
S
S
Tomizawa
Y
Y
Endo
M
M
Koyanagi
H
H
Nojiri
C
C
Oshiyama
H
H
Kido
T
T
Yokoyama
K
K
D000327:Adsorption; D000388:Air; D000925:Anticoagulants / Q000008:administration & dosage / Q000737:chemistry; D001672:Biocompatible Materials / Q000737:chemistry*; D001769:Blood; D001798:Blood Proteins / Q000032:analysis / Q000737:chemistry; D002315:Cardiopulmonary Bypass / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible / Q000737:chemistry; D015926:Complement C3a / Q000032:analysis; D005337:Fibrin / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006438:Hemodilution; D006493:Heparin / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D015151:Immunoblotting; D007958:Leukocyte Count / Q000187:drug effects; D010106:Oxygenators; D010976:Platelet Count / Q000187:drug effects; D013499:Surface Properties; D013997:Time Factors; D001620:beta-Thromboglobulin / Q000032:analysis
D000925:Anticoagulants; D001672:Biocompatible Materials; D001798:Blood Proteins; D020099:Coated Materials, Biocompatible; D001620:beta-Thromboglobulin; D015926:Complement C3a; D005337:Fibrin; D005340:Fibrinogen; D006493:Heparin